ID   UACC-3199
AC   CVCL_4042
SY   UACC 3199; UACC3199; University of Arizona Cell Culture-3199
DR   ATCC; CRL-2983
DR   BioSample; SAMN03471703
DR   cancercelllines; CVCL_4042
DR   GEO; GSM481329
DR   GEO; GSM3145743
DR   PharmacoDB; UACC3199_1633_2019
DR   Progenetix; CVCL_4042
DR   Wikidata; Q54973840
RX   PubMed=9778046;
CC   Population: Caucasian.
CC   Characteristics: ER-negative, PR-negative and ERBB2-positive (ATCC=CRL-2983).
CC   Derived from site: Metastatic; Axillary lymph node; UBERON=UBERON_0001097.
ST   Source(s): ATCC
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11
ST   D16S539: 12
ST   D5S818: 13
ST   D7S820: 10
ST   TH01: 9.3
ST   TPOX: 10,13
ST   vWA: 15,17
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 19
//
RX   PubMed=9778046; DOI=10.1038/sj.onc.1202086;
RA   Rice J.C., Massey-Brown K.S., Futscher B.W.;
RT   "Aberrant methylation of the BRCA1 CpG island promoter is associated
RT   with decreased BRCA1 mRNA in sporadic breast cancer cells.";
RL   Oncogene 17:1807-1812(1998).
//